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Abstract: The rich biology associated with steroids dictates a
growing demand for the new synthetic strategies that would
improve the access to natural and unnatural representatives of
this family. The recent advances in the field of catalysis have
1. Introduction
Due to the fact that steroidal hormones are of great importance
for the regulation of a wide range of cellular functions in eukar-
yotic organisms, and humans, in particular, this large and di-
verse family of natural products has played a central role in the
fields of medicine and drug discovery.[1] Historically, chemists
have played an important role in both helping to understand
the vital biological processes regulated by steroids as well as in
developing steroid-based medicines for the treatment of dis-
eases or improvement of the quality of human life. Needless to
say, these advances would not be possible without break-
throughs in synthetic chemistry and catalysis, including transi-
tion metal-mediated catalysis, asymmetric catalysis, and organ-
ocatalysis. Synthesis of steroids requires addressing many chal-
lenges including the installation of all-carbon quaternary ster-
eocenters,[2] multiple redox manipulations,[3] and assembly of
polycyclic ring systems with defined stereochemistries at the
ring junctions.[4] In this review, we summarize some of the re-
cent advances in the synthesis of steroids that have been
enabled by the advances in catalysis. It is primarily focused on
the studies that have emerged since 2014 and that have not
been reviewed elsewhere.[5] This Minireview does not cover
some of the important advances in closely related areas of asym-
metric non-steroidal terpene natural product syntheses.[6,7]
2. Syntheses Enabled by Transition Metal
Catalysis
2.1. Enantioselective Palladium-Catalyzed Dearomatizative
Cyclization for the Synthesis Steroid Boldenone Core[8]
Chiral phenanthrenone derived tricyclic cores bearing all-
carbon quaternary centers are present in numerous complex
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greatly impacted the field of natural product synthesis includ-
ing the synthesis of steroids. This article provides a short over-
view of the recent progress in the synthesis of steroids that was
enabled by the advances in catalysis.
terpenes and steroid natural products.[5m,9] An asymmetric
intramolecular Heck reaction[10] is a conventional approach to
construct these polycyclic cores bearing all-carbon quaternary
centers. Alternatively, in 2015, Tang et al.[8] reported an efficient
palladium-catalyzed asymmetric intramolecular dearomatiza-
tive cyclization[11] based on the earlier studies of the Buchwald
group[12] to afford various chiral phenanthrenones, some of
which contain many key features of the steroidal and terpenoid
frameworks (Scheme 1). They envisioned that bromoaryl-teth-
ered phenol 1 would undergo dearomatizative cyclization in
the presence of a chiral palladium catalyst to provide chiral
product 2 and its achiral congener 3. The tentative mechanism
Scheme 1. Competitive cyclization pathways for oxidative dearomatization.[8]
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for the formation of products 2 and 3 is depicted in Scheme 1.
Initially formed through the oxidative addition to aryl bromide,
intermediate II could potentially undergo two competing path-
ways in the presence of a base: 1) nucleophilic attack via the
C4 position of phenol leading to the formation of palladacycle
IIIa and eventually resulting in product 2 and 2) nucleophilic
attack via the C2 position of phenol providing the regioisomeric
achiral product 3. The intramolecular dearomatizative cycliza-
tion of 1 was optimized by screening various chiral palladium
catalysts. The use of novel P-chiral ligand containing diphenyl-
pyrrole substituent provided the best outcome with 94 % yield
and 92 % ee of the desired product 2. The substrate scope
study of this useful transformation revealed that the reaction is
compatible with the fluoro-, chloro-, and methoxy- substituents
in the aryl bromide portion of the substrate.
The reaction was also compatible with the presence of biaryl
and heteroaryl groups such as naphthalene, quinoline, and
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furan in aryl bromide end. The variation in tether length al-
lowed to construct both 5- as well as 7-membered rings. The
reaction outcome was not affected by varying the alkyl substit-
uent at the C4 position as both ethyl and butyl-substituted sub-
strates provided favorable outcome; however, the phenyl-sub-
stituted at the C4 (a) position substrate did not give any desired
product. The versatility and efficiency of this method were also
used to quickly set the core of the anabolic steroid boldenone
(Scheme 2). The key precursor 7 was prepared from Hajosh–
Parrish ketone-derived ketal 4 and bromide 5 following a three-
step sequence consisted of alkylation, triflation, and debenzyla-
tion. The subsequent asymmetric dearomatization reaction with
[{Pd(cinnamyl)Cl}2]/(R)-8 smoothly provided boldenone skele-
ton 9 in high yield (90 %) and high diastereoselectively (>99:1).
Remarkably, the use of [{Pd(cinnamyl)Cl}2]/(S)-8 granted access
to diastereomeric skeleton 10 (90 % yield, 98:2 d.r.) demonstrat-
ing the efficiency of this catalyst-controlled transformation.
Minireview
Scheme 2. Dearomatizative cyclization in the synthesis of boldenone skele-
ton.[8]
2.2. Enantioselective Total Syntheses of Furanosteroids
(–)-Viridin and (–)-Viridiol by Guerrero's Group[13]
Recently in 2017, the Guerrero group reported an elegant ap-
proach to furanosteroids, (–)-viridin and (–)-viridiol based on
an enantioselective intramolecular Heck reaction approach.[13]
While the racemic synthesis of viridin[14] and viridiol[15] was ac-
complished by Sorensen in 2004,[16] this late stage fragment
coupling based strategy may be amenable to the synthesis of
viridin analogs with modifications in D ring.
The synthesis began with the access of thioester 13 and
stannane 16 (Scheme 3). A known aryl triflate[17] was subjected
Scheme 4. Fragment assembly and synthesis of the precursor 23 to (–)-viridin and (–)-viridiol.[13]
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to a Heck alkenylation to get compound 11. Hydrogenation of
alkene and concomitant removal of the benzyl group followed
by treating the resulting cinnamic acid with neat chlorosulfonic
acid led to indanone 12. Finally, the functionalized indanone
13 was obtained after thioesterification and triflation of 12. On
the other hand, a known furan derivative[18] 14 was converted
into the A-ring furan fragment 16 in a 4-step sequence involv-
ing 1) chlorination of a primary alcohol using methanesulfonyl
chloride and triethylamine, 2) displacement of chloride by allyl
group using allylmagnesium chloride to get 15, 3) ring-closing
metathesis using Grubb's second-generation catalyst and
4) lithiation followed by stannylation.
Scheme 3. Synthesis of the key intermediates for the (–)-viridin and (–)-viridiol
synthesis.[13]
Next, the fragment coupling between 13 and 16 was exe-
cuted under Liebeskind stannane-thioester coupling condi-
tions[19] remarkably to get diketone 17 with aryl triflate intact
in good yields and on multigram scale (Scheme 4). The coupled
product 17 was then subjected for the stereodefining enantio-
selective intramolecular Heck reaction using Pd(0)-S-tBuPHOX
complex in presence of 1,2,2,6,6-pentamethylpiperidine (PMP)
to furnish (+)-18 in 75 % yield and high enantioselectivity
(>99 % ee). This reaction proceeds via the classical Heck reac-
Minireview
tion mechanism (Scheme 5), and the facial selectivity for the
conversion of 17A into 17B is determined by the chiral ligand
S-tBuPHOX. It is noteworthy that the use of PMP was required
to complete the conversion and reduce the alkene isomeriza-
tion which was otherwise observed with diphosphine ligands.
Scheme 5. Mechanism of the Heck reaction leading to (+)-18.
Compound 18, though contains the complete carbon skele-
ton of viridin, still lacks the required oxidation of the A-ring. To
install it, Upjohn dihydroxylation was carried out to get diol 19
diastereoselectively from α-face biased by the angular methyl
group. The following Swern oxidation and methylation led to
the methoxyketone 20 providing the required oxidation at C-3
via indirect means as the direct means of oxidation of this posi-
tion on 18 were unsuccessful. The TBS group in 20 was cleanly
removed by stirring in TFA to get compound 21 which was then
subjected for a three-step sequence involving 1) a temporary
protection of the D-ring ketone as a TBS-silyl-enol ether, 2)
stereoselective reduction of the A-ring ketone using BH3·THF,
and 3) desilylation by using Et3N·HF to reveal the D-ring ketone,
Scheme 6. Elaboration of (–)-23 and (+)-23 into (–)-viridin and (–)-viridiol.[13]
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to deliver keto alcohol 22 in 72 % isolated yields for three steps.
Even though allylic alcohol 22 may potentially be advanced to
(–)-viridin by hydroboration and selective alcohol oxidation, the
former step was unsuccessful. Consequently, enol-ether 22 was
epoxidized using AcOOH in methanol to give a mixture of dia-
stereomers (–)-23 and (+)-23.
The seemingly challenging diastreoselective monodemeth-
oxylation of dimethoxyacetals (–)-23 and (+)-23 was then suc-
cessfully performed using TMSOTf and hydride donor to respec-
tively give viridiol and epi-viridiol, albeit in low yields due either
to decomposition of reactant or product (Scheme 6). Both
epimers were then converted to viridin after TEMPO oxidation
completing an 18-step synthesis starting from commercial ma-
terials.
2.3. Synthesis of Natural and Enantiomeric Steroids via
Metallacycle-Mediated Annulative Cross-Couplings[20]
In 2017, Micalizio group reported an interesting and concise
approach based on the metallacycle-mediated cross-coupling
to access a series of natural and enantiomeric steroids.[20c] The
strategy involves the early construction of the C/D ring system
via a metallacycle-mediated annulative cross coupling[21,26] be-
tween an alkyne and a suitably functionalized chiral enyne fol-
lowed by a strategic formation of the C5–C6 bond after a suit-
able functionalization and activation of ACD tricycle. The enyne
24 was synthesized from (–)-epichlorohydrin either via a low
yielding two-step protocol involving 1) SN2 displacement of the
chloride by alkynyllithium derived from phenylpropargyl ether
and 2) opening of the epoxide by propenyl cuprate or a more
efficient three-step protocol involving 1) opening of the epox-
ide by alkynyllithium in presence of BF3·Et2O, 2) treating with
KOtBu and 3) SN2 displacement with propenyl cuprate. The
enyne 24 was then subjected for a unique titanium-mediated
annulative cross coupling with trimethylsilyl-phenylacetylene
(25) to deliverhydrindane 26 along with the exo-diene 27
(Scheme 7). This powerful transformation constructs three C-C
σ bonds and two stereocenters including one quaternary center
leading to an angularly substituted trans-fused hydrindane from
acyclic precursors. Mechanistically, this transformation was pro-
posed to proceed via a series of cascade events as depicted in
Scheme 7, which include 1) formation of titatanocycle interme-
diate 28; 2) an alkoxide-directed formation of metallacycle 29
followed by alkoxide exchange to generate 30 in high regio-
selectivity (>20:1 r.s.);[22] 3) diastereoselective intramolecular
[4+2] cycloaddition to give bridged metallacyclopentene 31
(>20:1 d.r.), 4) elimination to furnish tertiary allylic metal species
32, 5) isomerization to provide primary allylic metal species 33
and 6) stereoselective protonation via an allylic transposition to
furnish hydrindanes 26 and 27. After the key cyclization trans-
formation, the introduction of the C6 carbon and subsequent
construction of the B ring was investigated (Scheme 8). Thus,
the exocyclic methylene in 27 was cyclopropanated to give vin-
ylcyclopropane intermediate 34. It should be noted that the
yields of this reaction could be improved when the C-16 alcohol
is protected.
Minireview
Scheme 7. Titanium(IV)-mediated formation of the steroidal C/D-ring sys-
tem.[20]
Scheme 8. Elaboration of 27 into steroidal core 36.[20c]
The initial attempts to ionize 34 with the expectation that it
would undergo an electrocyclic ring-opening followed by an
intramolecular Friedel-Crafts alkylation were deemed unsuc-
cessful. However, it was found that the treatment of 34 with
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TiCl4 in nitromethane led to the steroidal product 36 in 68 %
yield. This process presumably proceeds via homoallylic cationic
intermediate 35, which is formed after protodesilylation, proto-
nation of resulting double bond and regioselective cyclyprop-
ane fragmentation[23] triggered by the in situ generated protic
acid arising from the reaction between the C-16 alcohol and
TiCl4. The subsequent intramolecular Friedel-Crafts alkylation
reaction and the loss of HBr led to 36.[24,25] This strategy was
later adopted to the synthesis of terpenoid euphane analogs
and investigated them as potential selective agonists of the
estrogen receptor beta (ER).[20a] The homopropargylic alcohol
37 underwent Ti(IV)-mediated annulation with alkyne 38 to
provide the functionalized hydrindane 39 (Scheme 9).
Scheme 9. Application to the synthesis of euphane analogs by Micalizio and
co-workers.[20a]
This intermediate was then subjected to various Lewis and
Brønsted acids to obtain diastereomeric steroid cores 40a and
40b. While the diastereomer 40a is favored under the achiral
Lewis acid catalysis with BF3·OEt2 (entry 1), the authors decided
to further improve the selectivity by utilizing combinations of
chiral Brønsted acids obtained by complexation of Lewis acids
and BINOL or its methylation of the C16 hydroxyl group of the
D-ring did not lead to the erosion in the reaction dr. Such cata-
lysts were previously explored by the Yamamoto[27] and Co-
rey[28] to achieve enantioselective polyene cyclization reactions
and turned out to be of particular utility in enhancing the for-
mation of the diastereomer 40a. Thus, the combination of (S)-
BINOL and SnCl4 at –78 °C resulted in the conversion of 39 to
40a in 50 % yield and >20:1 dr. This transformation proceeds
Minireview
Scheme 10. Dearomatizative rearrangement leading to the formation of steroidal skeleton with C19 methylation by the Micalizio group.[20a]
through the protonation of 41a and follows by the intramolec-
ular Friedel-Crafts reaction through the intermediacy of 41b
(Scheme 9). This remarkable reaction is dependent on the chi-
rality of BINOL, and the use of the (R)-BINOL as the ligand in-
stead led to 1:1 dr. In addition, the methylation of the C16
hydroxyl group of the D-ring did not lead to the erosion in the
reaction dr.
The diastereomer 40a and related compounds were sub-
jected to the oxidative dearomatizative rearrangement leading
to the steroidal cores containing the C19 methylation. Thus, the
treatment of 40a led to the formation of the deprotected C3
hydroxyl (Scheme 10). The reaction of this resultant intermedi-
ate with phenyliodine(III) diacetate (PIDA) results in intermedi-
ate 42 that undergoes subsequent rearrangement to provide
the dearomatized carbocation 43, deprotonation of which leads
to 44.
2.4. Pd-Catalyzed Intramolecular Alkenylation to Form
4,5-Spirocyclic Skeleton of Phainanoid A[29]
In 2017, Dong and co-workers published a palladium-catalyzed
intramolecular alkenylation approach to access the strained
cyclobutane-containing 4,5-spirocycle of the western part of
phainanoids.[29] This approach featured Pd-catalyzed intra-
molecular alkenylation of an enolate that provided the spirocy-
clic cyclobutane-containing portion of phainoids.
These model studies began by first developing a scalable
route to allylic epoxide 52 (Scheme 11). This compound was
generated from the commercially available geranyl acetate 45.
Thus, 45 was subjected to a three-step sequence involving cop-
per-catalyzed allylic coupling, chemoselective epoxidation, and
oxidative cleavage of the epoxide that resulted in aldehyde 46
in 64 % yield. Subsequently, the Still-Gennary variant of the
Horner–Wadsworth-Emmons olefination was employed to af-
ford Z-olefin-containing 48 in 79 % yield. The reduction of the
ester moiety in 48 with DIBAL-H and subsequent two-step oxid-
ation of the resultant alcohol 49 afforded aldehyde 50 in 70 %
yield over 3 steps. Finally, basic-alumina-promoted aldol con-
densation between 50 and 3-coumaranone (51) afforded allylic
epoxide 52 with Z-selectivity.
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Scheme 11. Synthesis of precursor 52 for the model studies toward the syn-
thesis of phainanoid A by the Dong group.[29]
With the efficient, scalable synthesis of 52 in hand, the syn-
thesis of the western part of phainanoids was completed
(Scheme 12). Lewis acid mediated polyene cyclization with
SnCl4 was employed to obtain tricyclic alcohol 53 with a trans-
decalin core in 70 % yield. Subsequent DMP oxidation and trifla-
tion of ketone 54 with Comins' reagent afforded vinyl triflate
55 in 46 % yield over 2 steps. Previous studies showed that the
challenging selective reduction of a trisubstituted olefin in the
presence of a vinyl triflate could be obtained via Pd/C-catalyzed
hydrogenation with an H2-balloon. This method was utilized to
obtain vinyl triflate 56 in 80 % yield. Finally, they attempted to
form the benzofuranone-based 4,5-spirocyclic motif with and
Minireview
exocylic olefin. Previous work by Helquist and co-workers indi-
cated that tert-butyl-substituted phosphine ligands could pro-
mote palladium-catalyzed intermolecular alkenylation of ket-
ones.[30] Based on these findings Dong attempted the intra-
molecular alkenylation of vinyl triflates with Pd(OAc)2 and
QPhos. They observed the base had a significant effect on the
reaction, and LiOtBu was superior compared to LiHMDS,
KHMDS, NaHMDS, KOtBu, NaOtBu, and Cs2CO3. They also found
that the reaction performed best under moisture-free condi-
tions. Utilizing the optimized conditions from the model stud-
ies, they successfully performed the intramolecular alkenylation
of 56 to afford the hexacyclic western part of the phainanoids
(57).
Scheme 12. Completion of the synthesis of the western portion of phainanoid
A by the Dong group.[29]
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2.5. Application of the Transformations Involving
Transition Metal-Catalyzed Hydrogen Atom Transfer (HAT)
to the Synthesis of Steroids
Transition metal-catalyzed reactions involving HAT have been
of great utility to the synthesis of steroids and terpenoids. While
many applications of HAT reactions are focused on introduction
of oxygenation via olefin hydration under mild conditions, sev-
eral recent applications feature the application of HAT reaction
for the C-C bond constructions that result in the formation of
challenging motifs present in various steroids. Below we pro-
vide a brief overview of the recent applications of such transfor-
mations and highlight their use in the synthesis of aplysiasecos-
terol by the Li group[31] and construction of (–)-nodulisporic
acid C by the Pronin group.[32]
2.5.1 Mukayiama's Hydration for the Diastereoselective
Introduction of Tertiary Alcohols in the Syntheses of
Steroids Cortistatin A,[35] Ouabagenin[36] and Linckosides A
and B[37]
Transition metal-catalyzed transformations resulting in the net
Markovnikov's hydration of the alkenes represent powerful and
mild methods for the introduction of hydroxyl groups into com-
plex substrate.[33] These transformations typically proceed in the
presence of Co(II) or Mn(II) salts and require molecular oxygen
and silane. The mechanism of Mukayiama hydration[34] is not
completely understood; however, it is believed to proceed
through the formation of transition metal hydrides, that react
with alkenes to accomplish hydrogen atom transfer (HAT) that
results in the species with radical-like properties (Scheme 13A).
These species undergo further reaction with molecular oxygen
and the resultant peroxide species are being reduced by silane
and Co(II). Importantly, these conditions may result in different
stereoselectivities then what is observed in more traditional
hydration reactions that proceed through the carbocationic
intermediates.
This feature has been explored by the Baran group for the
installation of the C5 oxygenation in their synthesis of cortisatin
A (Scheme 13B and C).[35] In order to introduce the α-C5 oxygen
required for the synthesis of cortistatin A, Baran group first ex-
plored the hydration of the intermediate 58. However, the un-
desired -C5 hydroxylated product 59 was formed instead. The
authors rationalized this selectivity by proposing that the reac-
tion mechanism involves a C5 radicals or a related species de-
noted by 60 and 61 (Scheme 13B). These radical intermediates
differ by the configuration of the radical containing C5 carbon.
Due to the presence of the α-C1/α-C2 epoxide moiety, the
intermediate 61 containing pseudoaxial –NHCHO group is less
favored and the reaction happens through 60 that contains cis-
A/B ring junction. This mechanistic hypothesis prompted the
authors to examine other substituents at the A ring. As a result
of this studies, the hydration of compound 62 leading to inter-
mediate 63 with the desired α-C5 configuration was identified
(Scheme 13C). The formation of 63 may potentially happen
through different conformers 64 and 65. The absence of the
α-C1/α-C2 epoxide allows now to achieve trans-AB ring junc-
tion in 65, which is the reactive intermediate, through which
the formation of 63 happens. Importantly, the facile formation
of 65 enabled the completion of the synthesis of cortistatin A.
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Scheme 13. A. The mechanism of Mukayiama hydration. B. C. Application of the Mukayiama hydration in the synthesis of cortistatin A by Baran and co-
workers.[35]
Subsequently, the Baran group successfully implemented
this strategy in the synthesis of polyoxygenated cardiotonic
steroid ouabagenin from progesterone.[36] As progesterone
does not contain the -C14 hydroxyl group, Baran and co-work-
ers installed this moiety using Δ14-alkene-containing intermedi-
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ate 66 (Scheme 14). Thus, treatment of 66 with molecular oxy-
gen, phenylsilane and Co(acac)2 as the reaction promoter re-
sulted in the formation of 67 as the 8:1 mixture of /α isomers.
The selective formation of the -isomer may be explained by
the higher stability of the cis-hydrindane conformer of the
Minireview
C14-radical intermediate than the corresponding trans-
hydrindane one. This strategy for the diastereoselective installa-
tion of the tertiary alcohols at the ring junction of the steroid
skeleton was recently utilized by the Yu and co-workers in their
synthesis of linckosides A and B (Scheme 15).[37] Surmising that
the Δ7-alkene of precursor 68 would preferentially react to form
the -C8 hydroxyl group, Yu and co-workers successfully carried
the hydration of 68 to form advanced intermediate 69 that was
later elaborated into linckosides A and B.
Scheme 14. Application of the Mukayiama hydration in the synthesis of
ouabagenin by Baran and co-workers.[36]
Scheme 15. Application of the Mukayiama hydration in the synthesis of
linckosides A and B by Yu and co-workers.[37]
2.5.2 Application of the Transformations Involving Iron-
Catalyzed Hydrogen Atom Transfer (HAT) to the Synthesis of
Aplysiasecosterol by Li and Co-Workers[31]
Aplysiasecosterol is a natural steroid derivative with a highly
reorganized skeleton. While this molecule features many func-
tionalities present in steroids, its assembly required the devel-
opment of new synthetic strategy, in particular, for the con-
struction of the highly substituted cyclopentane ring. Li's group
performed the first asymmetric total synthesis of the 9,11-seco-
steroid aplysiasecosterol in 2018.[31] A convergent synthesis was
accomplished to establish the stereocenters shown in
Scheme 16 prior to a HAT based radical cyclization to construct
the cyclopentaine ring of aplysiasecosterol in a selective man-
ner.
The Li group found that a desymmetrizing lactolization reac-
tion could be performed using the Roush enantioselective allyl-
ation of symmetric aldehyde 73 with boronic ester 74 to bypass
the traditional Corey–Bakshi–Shibata reduction and streamline
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Scheme 16. Retrosynthesis of aplysiasecosterol.[31]
the synthesis providing 75 in 85 % yield and 9:1 er as deter-
mined by Mosher esterification followed by the 19F NMR analy-
sis (Scheme 17). After the subsequent enantioenrichment of 76,
the benzyl acetal formation was accomplished with BnOH and
MsOH. This intermediate was then converted into α,-unsatu-
rated enone 77 using Nicolaou's protocol (silyl enol ether for-
mation then IBX/MPO oxidation) in 77 % yield from 76. The left-
hand segment synthesis was finished with annulation initiated
with V-40 and(TMS)3SiH (78 % yield), subsequent silyl enol ether
formation, NBS bromination, and ozonolysis to give 71. (91 %
yield over 3 steps).
Scheme 17. Synthesis of the key intermediate 71 in the synthesis of aplysiase-
costerol.[31]
For the synthesis of the right-hand segment 72, Li and co-
workers initially utilized Myer's alkylation; however, the process
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was tedious thus decreasing the efficiency. Therefore, a differ-
ent route commencing with the formation of 80 from 79 using
Sharpless asymmetric dihydroxylation was developed (cf.
Scheme 18). This followed by the Grieco elimination/ozonolysis
sequence to derive one carbon shorter homologue 81 (85 %, 3
steps). The primary alcohol moiety of 81 was esterified under
the Mitsunobu conditions to provide 82 (98 % yield), which set
stage for the Aggarwal's lithiation-borylation chemistry that in-
volved a stereoselective lithiation with (+)-sparteine. The result-
ant organolithium species was alkylated with alkyl pinacol-
borane to provide 83 with the desired configuration of the C17
stereocenter in 93 % yield. Treating 83 with tBuLi allowed for a
Zweifel-Evans olefination to give 84 (93 %, 15:1 dr at C17). This
compound was further elaborated to the corresponding alde-
hyde by a sequence involving silyl deprotection and Dess–
Martin oxidation to provide aldehyde 72 for the coupling with
71.
Scheme 18. Synthesis of the intermediate 72 by Li and co-workers.[31]
Subsequently, 71 and 72 were linked by a radical Reformat-
sky type of aldol addition reaction that provided the anti-aldol
product in 70 % yield (Scheme 19A). This aldol addition product
was converted into the corresponding aldol condensation prod-
uct 70 by the elimination of water using Burgess reagent (58 %,
2 steps). From here, the Li group envisioned that the key highly
functionalized cyclopentane moiety of aplysiasecosterol could
be installed using Fe(III)-catalyzed radical cyclization developed
by the Baran group. The tentative mechanism of this transfor-
mation is depicted in Scheme 19B and is likely to involve a HAT
resulting in a radical intermediate.[38] Upon screening various
ligands for the Fe(III) catalyst (acac, ox, dibm, and dpm, etc.) the
optimal conditions were identified to provide 85 in 56 % yield.
This compound was subsequently subjected to deprotection
that provided aplysiasecosterol in 92 % yield (2 steps). It is of
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note that the cyclization conditions were extended to produce
analogs with similar yield. From this work, Li and co-workers
have provided an advantageous route that can be used to syn-
thesize 9,11-secosteroids in a convergent fashion.
Scheme 19. A. Fragment coupling and completion of the synthesis of aplys-
iasecosterol. B. Proposed mechanism for the iron(III)-promoted HAT cycliza-
tion.[31]
2.5.3 Application of the Transformations Involving Iron-
Catalyzed Hydrogen Atom Transfer (HAT) to the Synthesis of
Aplysiasecosterol by Pronin and Co-Workers[32]
Pronin's group recently applied iron-catalyzed HAT cyclization/
aldol addition sequence to establish the eastern portion of ind-
ole diterpenoid, (–)-nodulisporic acid C (Scheme 20).[32,39] The
synthesis began with the copper-catalyzed asymmetric conju-
gate addition to 86 using the JosiPhos derivative SL-J015–1 to
prepare the silyl-enol ether 87 in 95 % yield and 73 % ee. This
silyl enol ether underwent an addition catalyzed by indium (III)
bromide to the TBS-protected pent-4-yn-1-ol,[40] and the follow-
ing acid work-up provided access to 88 containing a quaternary
stereocenter. This intermediate was subjected to a three-step
sequence that included the formation of cyanohydrin, Sharpless
allylic oxidation and primary alcohol oxidation by Dess–Martin
periodane to provide the dialdehyde 89 in 40 % yield over 3
steps. Subjecting 89 to Fe(acac)3 with PhSi(OiPr)H2[38] resulted
in diastereoselective formation of two vicinal quaternary cen-
ters and concomitant aldol addition. This followed by the acidic
work up with HCl and then base to cleave the cyanohdrine
moiety and provided 90 in 41 % yield and 10:1 d.r. The high
diastereoselectivity of this reaction is attributed to the pseudo-
axial substituent at the C2 position. The substrate 90 was esteri-
fied (Piv2O, Et3N) and then subjected to Horner–Wadsworth-
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Emmons olefination to provide the fully functionalized eastern
portion of (–)-nodulisporic acid C (91), which was subsequently
elaborated to the natural product itself.
Scheme 20. Application of iron(III)-promoted HAT cyclization/aldol addition
cascade in the synthesis of (–)-nodulisporic acid C by Pronin and co-work-
ers.[39]
2.5. Application of the Directed Copper-Catalyzed C-H
Oxidation in the Synthesis of Pergularin, Utendin, and
Tomentogenin by the Baran Group[41]
While many steroids carry a significant degree of skeletal oxid-
ation, synthesis of steroids with high degree of oxidation repre-
sents a significant challenge. Recently, new approaches based
on the late-stage selective C-H oxidation started to emerge and
be applied to complex steroid synthesis. Thus, based on the
promising results obtained by the Schonecker group,[42] Baran
and co-workers have developed a powerful method for the in-
troduction of the -C12 hydroxylation at steroid skeleton under
aerobic conditions (Scheme 21). This approach requires the
presence of the C17 ketone that is then being converted to an
imine functionalized with a 4-methylpyridyl moiety. This auxil-
iary is required for achieving chelation with Cu to form dimer
94 and for directing the oxidation to the -C12 position result-
ing in 95. The imine moiety of 95 could be subsequently re-
moved by the work-up with saturated solution of Na4TMEDA.
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The Baran group was able to demonstrate that this oxidation
protocol is rather general and could be applied to a variety of
substrates to obtain the corresponding oxidized products
93A-93H in preparatively useful yields (40–90 %).
Scheme 21. Cu-catalyzed C-H auxiliary-directed C-H oxidation of the C12 po-
sition of steroidal skeleton by the Baran group.[41]
This protocol was subsequently applied to the synthesis of
steroids utendin, pergularin and tomentogenin that feature -
C12 oxidation of the C ring and contain highly oxidized D-ring
(cf. Scheme 22). This synthesis commenced with inexpensive
DHEA (96) that was subjected a 2 step sequence to provide
auxiliary-containing product 97 (35 % yield). This substrate was
subjected to the aerobic oxidation in the presence of
Cu(MeCN)4PF6 and sodium ascorbate to provide -C12 oxidized
product 93D in 40 % yield. This trans-C/D ring-containing inter-
mediate was converted to 98 in 34 % yield via a 3 step se-
quence that involved the formation of silyl enol ether (TMSOTf,
Et3N), and subsequent Saegusa oxidation (Pd(OAc)2, FeCl3) fol-
lowed by the silica gel promoted deconjugation of the resultant
enone moiety. Intermediate 98 was next subjected to Mn(II)-
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promoted Mukayiama hydration conditions that afforded 99 in
67 % yield.
Scheme 22. Directed C-H oxidation in the synthesis of pergularin, utendin,
and tomentogenin by the Baran group.[41]
It is noteworthy that despite the fact that substrate 98 con-
tains two alkenes, only the trisubstituted Δ14-alkene moiety re-
acted under these conditions. The diastereoselectivity of this
reaction was consistent with the observations made by the
Baran group in their studies on the synthesis of ouabagenin
(cf. Scheme 14).[38] The resultant product 99 was treated with
lithiated ethyl vinyl ether in the presence of LaCl3 to provide
100 upon hydrolysis of the vinyl ether moiety (51 % yield). The
allylic cyclopropane functionality of 100 was cleanly converted
into the homoallylic bromide by the treatment with HBr. The
subsequent silver(I)-assisted solvolysis of this intermediate re-
sulted in the corresponding homoallylic trifluoroacetate that
was hydrolyzed to form pergularin by the treatment with aque-
ous trifluoroacetic acid (60 % yield). This followed by the stereo-
selective reductions that were used to convert pergularin to
utendin (NaBH4, 75 % yield) and then utendin to tomentogenin
(Pd/C, H2, 80 % yield).
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2.6. Rh-Catalyzed Cyclopropanation with Quinone Diazides
in the Synthesis of Cycloartenol Core by the Baran
Group[45]
Cyclopropane-containing steroids such as cycloartenols repre-
sent challenging synthetic targets. In 2014, Baran and co-work-
ers reported a new approach to the synthesis of such steroids
that is based on an intramolecular cylopropanation with quin-
one diazides using Rh(II)-based catalysts and provided steroidal
core 109 that may serve as the intermediate for the synthesis
of cycloartenols and other classes of steroids.[43]
These studies commenced with the preparation of the frag-
ments 103 and 106 (Scheme 23). Thus, bromophenol derivative
101 was subjected to a 4 step sequence that involved Sonaga-
shira coupling with TMS-protected acetylene (PdCl2(PPh3)2, CuI),
reduction of the nitro group (Zn, FeSO4), and subsequent instal-
lation of the triazene moiety via the intermediacy of the diazo-
nium salt (NaNO2, HCl then HNiPr2). This sequence culminated
by base-promoted cleavage of the silane protection (K2CO3,
MeOH) to provide triazene 102 in 68 % yield (4 steps). Com-
pound 102 was then subjected to Ni(0)-catalyzed hydroalumi-
nation of the alkyne moiety (NiCl2(PPh3)2, DIBAL-H) that fol-
lowed by the conversion of the organoaluminum intermediate
to vinyl iodide 103 (51 % yield) by its reaction with NIS. The
synthesis of intermediate 106 commenced with 2-methyl-2-cy-
clopentenone 104 (Scheme 23). This compound was subjected
to conjugate addition of vinyl cuprate followed by the capture
of the enolate as the TMS-enol ether. After purification, this
Scheme 23. Rh(II)-catalyzed intramolecular cyclopropanation in the synthesis
of the cycloartenol core by the Baran group.[43]
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silyl enol ether was converted into the corresponding lithium
enolate, which was cross-coupled with -methallyl chloride
([PdCl2(PPh3)2], MeLi, -methallyl chloride) resulting in com-
pound 105 (83 % yield, 10:1 dr). This intermediate was sub-
jected to protection to install 1,3-dioxalane moiety (ethylene
glycol, pTsA), ozonolysis (O3, PPh3) and aldol condensation
(LiOH, iPrOH followed by PPh3, CBr4) to provide key intermedi-
ate 106 in 47 % yield over 4 steps.
With both intermediates in hand, their coupling was accom-
plished next. Thus, 103 was subjected to Mg/halogen exchange
with iPrMgCl·LiCl, and the resultant Grignard reagent was em-
ployed as a nucleophile for the Cu(I)-catalyzed 1,4-conjugate
addition to 106 followed by the capture of the resultant enolate
with TMSCl to form the corresponding silyl enol ether. The sub-
sequent reduction of the styrene moiety (Pd/C, H2) provided
intermediate 107 in 69 % yield over 2 steps. This compound
reacted with Eschenmoser's salt and Li2CO3 to install the exocy-
clic enone moiety and subjected to deprotection of 1,3-dioxa-
lane (SiO2). The resultant compound was treated with trifluoro-
acetic acid, which resulted in the deprotection of the MOM
group and formation of the quinone diazide 108. Quinone diaz-
ide was then treated with various Rh(II) salts to accomplish
intramolecular diastereoselective cyclopropanation proceeding
through Rh-based carbenoid and leading to steroidal core 109.
The evaluation of various catalysts helped to identify [Rh2(esp)2]
as the best catalyst of this transformation that afforded 109 in
80 % yield.
2.7. Pd/Ni-Promoted Ulman Coupling in the Synthesis of
the Batrachotoxin Core by the Inoue Group[44]
Batrachotoxin is a steroidal alkaloid with neurotoxic properties
isolated in 1968 from the skin of Columbian poison-arrow
frogs.[45] Batrachotoxin features multiple fused rings and high
level of skeletal oxidation and represents a formidable synthetic
target.[7k,46] In 2018 Inoue's group disclosed a new approach
that allowed for the synthesis of batrachotoxin's steroidal core
110 (Scheme 24), which could potentially be expanded to the
synthesis of batrachotoxin.[44] Intermediate 110 was generated
from 111 through the intramolecular Pd/Ni-catalyzed Ullman
Scheme 24. Retrosynthetic analysis of Inoue's approach to batrachotoxin.[44]
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coupling reaction. Compound 111, in turn, was prepared by
the radical addition of 113 to 112, which represents another
the key step in the synthesis of 110.
The synthesis of intermediate 112 commenced with the
asymmetric Noyori transfer hydrogenation of prochiral sub-
strate 114 resulting in the desymmetrized reduction product in
96 % ee (Scheme 25). The following TBS protection resulted in
115 (59 % yield, 2 steps). This product was enolized in the pes-
ence of the Commins' reagent to provide 116 (84 %), which
was converted to 112 in 3 steps via the oxidative cleavage of
the terminal alkene followed by the aldol condensation with
malononitrile (80 %, 3 steps). The synthesis of 113 commenced
with 117 that was derived from Wieland-Miescher ketone. This
compound was treated with lithiated vinyl ethyl ether, and the
resultant product was subjected to 1,3-dioxolane hydrolysis/
intramolecular acetalization (CH(OMe)3, MeOH, CSA) followed
by the oxidative cleavage of the vinyl ether moiety (RuCl3,
NaIO4) to provide 118 in 58 % yield.
Scheme 25. Synthesis of the key intermediates.[44]
With both fragments 112 and 113 in hand, the subsequent
coupling was attempted (Scheme 26) using Et3B and molecular
oxygen. The mechanism of this transformation is depicted in
Scheme 26 and commences with Et3B reacting with oxygen and
producing ethyl radical. Ethyl radical then abstracts Te from the
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C-Te bond of 113. The resultant acyl radical undergoes a subse-
quent decarbonylation to provide an α-alkoxy radical with fixed
Scheme 26. Coupling of intermediates 112 and 113 leading to 111.[44]
Scheme 27. A. Synthesis of batrachotoxin core 110. B. Potential mechanism
for the Pd/Ni-catalyzed Ullman coupling.[44,48]
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stereochemical configuration.[47] The following addition to the
electron-deficient alkylidenemalonitrile 112 provides a stabi-
lized radical that is subsequently trapped with Et3B to form
boron enolate, which hydrolyzes upon work-up and provides
111 (α-C11-H, 41 % yield; -C11-H, 27 % yield).
With this in hand, the intermediate 111 was elaborated to
batrachotoxin core 110 (Scheme 27A). These studies com-
menced with the oxidation of the malononitrile moiety with
monoperoxyphthalate to provide 120, which was subjected to
ethanolysis under the basic conditions (NH3, EtOH) leading to
121 (α-C11-H, 60 % yield; -C11-H, 61 % yield). This substrate
contains both vinyl bromide and vinyl triflate moieties that pro-
vide handles for the subsequent reductive cyclization.
The Inoue group first employed Ni-catalyzed Ullman cou-
pling (NiCl2, 2,2′-bipyridine, Zn, CH3CN, Py, 50 °C); however, this
transformation did not lead to high yields of 110 due to the
slow oxidative insertion into C-OTf bond. Subsequently, a modi-
fied protocol developed by the Weix group and utilizing a dual
Pd/Ni catalytic system was employed.[48] Low yields were ob-
served when the transformation was attempted catalytically;
however, the use of stoichiometric metal complexes tripled the
yields of 110. While the actual reaction mechanism is yet to be
clarified, based on the Weix group proposal, a catalytic cycle
depicted in Scheme 27B and potentially involving a bimetallic
intermediate could be envisioned.
3. Syntheses Enabled by the Lewis Acid
Catalysis
3.1. Cu(II)-Catalyzed Enantioselective Tandem Michael/
Aldol Reactions in the Synthesis of Cardiotonic Steroids by
Nagorny and Co-Workers[49]
Cardiotonic steroids represent a large family of steroids with
unique structural features such as characteristic -C14 alcohol,
-C17 heterocyclic ring, and an unusual cis-C/D ring junction
pattern, which imparts a rigid “U” shape to the molecule.
Around a thousand of different natural cardenolides have been
isolated to date from various plant and animal sources. Consid-
ering that cardenolides are involved in regulating vital biologi-
cal processes and for centuries have been used as therapeutic
agents, the total synthesis of cardenolides has attracted consid-
erable attention. Despite these numerous studies, the synthesis
of highly oxygenated cardenolides, such as ouabagenin, repre-
sents a significant challenge, and only recent advances in catal-
ysis and synthetic methodology allowed to overcome some of
these challenges. Such landmark efforts include the recently
disclosed syntheses of ouabagenin and 19-hydroxysarmento-
genin by the Deslongchamps,[50] Baran,[36] and Inoue[51] groups
as well as the studies by the Nagorny group that will be the
focus of this mini-review.[49]
The tandem Michael/aldol reaction approach to cardiotonic
steroids is summarized in Scheme 28. This approach is based
on the presumption that enones 123 and -keto esters 122
could undergo a stereoselective Michael reaction to provide
124. Subjecting 124 to tandem aldolization under acidic or ba-
sic conditions would lead to 125, which represents a fully func-
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tionalized cardenolide skeleton that could be further elaborated
into steroids 126 featuring various oxidation patterns.
Scheme 28. Cu(II)-catalyzed tandem Michael/aldol reaction approach to the
synthesis of cardiotonic steroids.[49]
Michael reactions are sensitive to the substrate sterics, and
the transformations leading to products like 124 that contain
vicinal quaternary/tertiary all-carbon stereocenters are very
rare. After screening a variety of conditions, Nagorny and co-
workers identified Cu(II) salts as unique catalysts for this trans-
formation under no solvent conditions. Based on these findings,
in 2015 Nagorny group demonstrated that the formation of 130
is possible in a highly enantioselective and diastereoselective
fashion from simple and readily available building blocks 127
and 128 (Scheme 29).[49g] Thus, it was demonstrated that read-
ily available chiral bis(oxazoline) copper(II) complex 129 could
promote Michael reactions with high levels of stereocontrol and
the stereochemistry required for their subsequent elaboration
to natural cardiotonic steroids (Scheme 29A). These Michael ad-
ducts could be subjected to various acidic or basic conditions
that promote the intramolecular aldolization and provide vari-
ous steroid-like cores 130A-J. The choice of the cyclization con-
ditions was of particular importance for establishing the stereo-
chemistry of the CD ring junction. By using DBU as base in THF,
the Michael adducts were converted into products 130A-F with
unnatural α-configuration of the C13/C14 stereocenters in good
to excellent yields and selectivities. Alternatively, treating the
substrate with Cs2CO3 in DMF at 140 °C led to the product
130G possessing natural -C13/-C14 configuration. Similarly,
subjecting the Michael adducts to 2 step conditions involving
pre-cyclization of the B-ring using pyrolidinium acetate fol-
lowed by the formation of the C-ring with LiHMDS or NaHMDS
led to products 130I-J. Finally, the reaction with -ketocarbox-
ylic acid instead of ester (i.e. 142, R1=H), led to the formation
of nor-steroid skeleton 130H in good yield and selectivity
(85 %, 8:1 dr, 93 % ee, gram scale).[51c] The tentative mechanism
of this transformation is depicted in Scheme 29C. Unlike the
majority of other Cu(II)Box-catalyzed reactions, 129 is proposed
to bind and activate nucleophile 131 rather than enone electro-
phile. The chelation of 129 and 131 leads to the formation of
complex 132 that then transfers a proton to the enone and
results in Cu(II)-based chiral enolate 133. The subsequent Mich-
ael reactions presumably happens through an open transition
state 134 and results in the corresponding product 136.
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Scheme 29. Enantioselective Cu(II)Box-catalyzed Michael/aldol cascade ap-
proach to cardenolide core. A. Overall transformation. B. Substrate scope. C.
Tentative reaction mechanism.[49c,49g]
These studies were subsequently translated into the synthe-
sis of more complex cardenolide cores 146 and 147
(Scheme 30) that were later elaborated to a variety of natural
cardenolides.[49a,d,e] The modified approach required adjusting
the oxidation state of both the -keto ester and enone frag-
ments in order to install the C3 and, optionally, C11 oxygen-
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ation. To address the problems associated with the installation
of the C3 stereochemistry, vinyl chloride-containing -keto es-
ter 137 was employed. -Keto ester 137 reacted with either the
achiral enone 138 or prepared in 3 steps OBz-containing chiral
enone 139 (Scheme 30). In the former case, the reaction was
catalyzed by chiral catalyst 129 that promoted the formation of
Michael adduct 140 in 92 % yield, 92 %ee, >20:1 dr. This com-
pound was then cyclized with pTsA to provide functionalized
steroidal core 142 (57 % yield, >20:1 dr).
Scheme 30. Enantioselective and diastereoselective Cu(II)-catalyzed Michael/
aldol cascade reactions for the synthesis of functionalized cardenolides cores
146 and 147.[49a,d,e]
In the case of chiral enone 139, the Michael reaction with
137 was catalyzed by Cu(OTf )2 (50 mol-%) and resulted in the
diastereoselective formation of product 141 in 70 % yield as
well as a monocyclized aldol product resulting from 141 (20 %
yield). Subjection of both of these compounds to pTsA in the
subsequent step resulted in the formation of aldol adduct 143
(59 % yield from 139). Alternatively, the formation of 143 from
139 and 137 could be executed in a single operation (45 %
yield, 20:1 dr) by carrying both steps in one pot. In both cases
the stereoselective formation of all 5 new stereocenters was
imposed by the C11-OBz group-containing stereocenter.
The aforementioned protocols enabled the concise forma-
tion of the steroidal cores 142 and 143 on multigram scale.
Both of these intermediates contained the desired stereochem-
istry and oxygenation with the exception of the α-C13/α-C14
stereocenters at the CD ring junction. However, our DFT calcula-
tions indicated that the natural -C13/-C14 configuration
present in 144 and 145 has higher thermodynamic stability.
Therefore, 142 and 143 were subjected to retro-Aldol/Aldol se-
quence resulting in the net epimerization of the C13/C14
stereocenters and providing 144 and 145 in 64 % and 68 %
(brsm) respectively. These products underwent a global reduc-
tion with DIBAL-H followed by the solvolysis of vinyl chlorides
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to generate unsaturated C3 ketones in an efficient one-pot
transformation (71 % yield, 8:1 dr and 72 % yield, 8:1 dr for 146
and 147, correspondingly). Both advanced intermediates were
produced in only 6 steps (LLS) on a multigram scale and con-
tained all of the necessary functionalizations to be advanced to
various cardiotonic steroids (Scheme 31 and Scheme 32).
Scheme 31. Elaboration of core 147 into cardenolide ouabagenin.[49a]
More advanced intermediate 147 contains oxygenations at
the C3, C11, C14, C17, and C19 positions as well as the unsatu-
ration at the C-5 position, which is critical for its rapid elabora-
tion to various highly oxygenated cardenolide ouabagenin
(Scheme 31).[51a] The presence of the additional C1/C5 oxygen-
ation in ouabagenin makes this important natural product to
be one of the most complex targets among the cardiotonic
steroids. The synthetic studies towards ouabagenin com-
menced with the reduction of the Δ7-olefin of 147 with LiDBB,
followed by a basic work-up with NaHCO3 to provide 148.
Polyol 148 was then subjected to a 3 step sequence that in-
cluded acetylation of the C11, C17, and C19 positions (Ac2O, Py,
DMAP), diastereoselective reduction of the C3 ketone with K-
Selectride®, and C3-directed epoxidation of the Δ4-olefin with
m-CPBA (6:1 dr for epoxidation step) to afford 149 in 62 % yield.
The following oxidation of 149 with Pd(TFA)2 and NaOAc under
molecular oxygen atmosphere afforded 150 in 90 % yield. En-
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Scheme 32. Elaboration of cores 146/147 into various cardiotonic steroids.[49]
one 150 was subjected to another 3 step sequence to furnish
151 (62 % yield) as a single diastereomer. This was accom-
plished by deacetylation followed by the Δ1-epoxidation with
LiOH and H2O2 to generate the C1/C2 epoxide, as a single dia-
stereomer. The C19 hydroxyl of this bis-epoxide underwent se-
lective protection as the TIPS ether (TIPSCl, 2,6-lutidine) that
followed by the oxidation of the C11 and C17 hydroxyls to af-
ford 151. The reduction of the epoxide moieties of 151 repre-
sented a significant challenge due to the propensity of the re-
sultant product to undergo dehydration leading to a complex
mixture of enones. After extensive screening, the conditions
that involved the reduction of 151 with PhSeSePh (20 mol-%)
and N-Ac-l-Cys-OH under basic conditions resulted in the de-
sired product 152 in 87 % yield. Careful control of the N-Ac-l-
Cys and NaOH stoichiometry was required to avoid water elimi-
nation and subsequent aromatization of the A ring. Then 152
was subjected to a single pot diastereoselective reduction of
the C3 ketone with K-Selectride® followed by the protection of
the C3 and C17 alcohols as the TBS ether and enol ether, re-
spectively (TBSOTf, 2,6-lutidine). The resultant product was sub-
jected to another single pot procedure that involved the C11
ketone reduction under dissolving metal conditions to obtain
the equatorial C11 alcohol, followed by work-up with TBAF that
provided ouabagenin core 153 in 74 % yield over two steps.
Vinyl iodide moiety at C17 was then installed using Barton's
protocol to give 154 in 96 % yield. The final installation of the
C-17 butenolide was achieved via a four-step sequence involv-
ing: 1) a Stille coupling of vinyl iodide 154 with stannane 155,
2) TMS protection of the C11 and C14 alcohols, 3) diastereo-
selective hydrogenation of Δ16- double bond, and 4) global de-
protection of silyl-protecting groups with aqueous HF to afford
ouabagenin in 42 % over the final four steps.
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The aforementioned strategy for the assembly of ouaba-
genin could be generally applied to a variety of other cardio-
tonic steroids (Scheme 32).[49c,49d] Thus, key intermediate 147
was successfully elaborated to diastereomeric cardenolides
trewianin aglycon (12 steps, 14 % yield),[49a,9d] 19-hydroxy-
sarmentogenin (12 steps, 8 % yield),[49a,9d] panogenin (9 steps,
5 % yield)[49a] and 5-epi-panogenin (9 steps, 23 % yield)[49a,49d]
that have different configurations at the C5 and C11 stereocen-
ters. In addition, these efforts provided sarmentologenin (14
steps, 7 % yield) that lacks C1-oxygenation in comparison to
ouabagenin.
A similar strategy was used to convert the intermediate 146
lacking the C11 stereocenter into glycosylated cardiotonic ster-
oid cannogenol-3-O-α-l-rhamnoside (12 steps, 11 % yield) and
its analogs with modified sugar.[49d]
4. Syntheses Enabled by the Organocatalysis
The seminal studies of Hajos, Parrish, Eder, Sauer, and Wiechert
revolutionized the synthesis of steroids and terpenoids and
helped to reveal the power of organocatalysis for the synthesis
of complex natural products.[52] Not surprisingly, the develop-
ment of new organic catalysts and organocatalyzed tandem re-
actions is still of great importance to the synthesis of steroids.
While many modern studies are focused on improving the syn-
thesis and formation of functionalized Hajosh-Parrish and Wie-
land-Miescher ketones, the developments in organocatalysis al-
low to achieve rapid formation of significantly more complex
intermediates. This subsection of the minireview highlights
some of such studies that emerged from the groups of Haya-
shi,[53] Hong[54] and List.[55]
4.1. Pot-Economical Total Synthesis of Estradiol Methyl
Ether by the Hayashi Group[53]
Interested in developing rapid and economical ways for the
synthesis of pharmaceutically important natural products,[56]
Hayashi and co-workers recently reported a highly pot-econom-
ical synthesis[53] of estradiol methyl ether using proline-derived
organocatalyst 158 (cf. Scheme 33).[57] The highlight of their
synthesis involves an expedient stereo-controlled construction
of the intermediate 159 with all carbons necessary for installing
the steroid framework within the first pot. The reaction involves
diphenylprolinol trimethylsilyl ether (158) catalyzed asymmetric
reaction between nitroalkane 156 and 3-(p-methoxy-
phenyl)propenal 157. The mechanism of this transformation is
depicted in Scheme 34A. The condensation of 157 and 158
leads to the formation of iminium ion 162, which undergoes
an asymmetric Michael reaction with nitronate anion 163 de-
rived from 156. This results in an enamine-containing product
164 that undergoes highly selective addition to one of the ket-
one moieties of the 1,3-cyclopentanedione linked to the
enamine. Upon hydrolysis of the resultant iminium ion 165, the
bicyclic structure 166 containing five contiguous stereocenters
is obtained. The selectivity of this domino reaction is remarka-
ble and provides essentially a single diastereomer with very
high enantioselectivity (>99 % ee). This reaction was success-
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Scheme 33. Hayashi's pot-economical synthesis of estradiol methyl ether.[53]
fully telescoped with two other subsequent reactions: 1) stereo-
selective addition of cyanide followed by the formation of
xanthate ester 167 (cf. Scheme 34A), and 2) dehydration using
SOCl2 and pyridine to afford intermediate 159 in 78 % yield
Scheme 34. A. Mechanism for the formation of intermediate 167. B. Synthetic
intermediates for the pot-economical synthesis of estradiol methyl ether.[53]
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from 156 and 157 in the first pot (cf. Scheme 33). The simulta-
neous removal of nitro-group and xanthate in 159 was carried
out reductively using Bu3SnH and AIBN under microwave condi-
tion and resulted in 160. This intermediate was subjected a
two-step one-pot sequence involving diastereoselective reduc-
tion of the ketone and nitrile via sequential addition of LiBHEt3
at –78 °C and DIBAL at 0 °C. The resulting hydroxyl aldehyde
after TIPS protection (TIPSCl, imidazole) affords aldehyde 161
in 59 % yield from 160. What follows next is a remarkable six-
step one-pot sequence depicted in Scheme 33 that includes 1)
Krauss–Pinnick oxidation yielding 168 (Scheme 34B), 2) trans-
hydrindane-selective hydrogenation controlled by OTIPS group
and leading to 169, 3) acyl chloride 170 formation, 4) Friedel-
Crafts acylation 5), deprotection of the silyl group by the addi-
tion of MeOH leading to 171, and 6) reduction of benzyl ketone
to give estradiol methyl ether in 55 % yield. The synthesis high-
lights the idea of compatibility in one-pot transformations and
accomplishes the synthesis of estradiol methyl ether in five re-
action pots involving four purification steps.
The key domino reaction of diphenylprolinol silyl-ether me-
diated Michael reaction of nitroalkane and intramolecular aldol
reaction is quite general in terms of aryl group at 3-position of
propenal as various electron-rich (p-methoxy-, p-methyl-) as
well as electron-deficient (p-fluoro-, p-bromo-, p-chloro-,
o-fluoro-) aryl group containing enals afford bicycle [3,3,0]
nonane frameworks with excellent enantioselectivity.
4.2. Organocatalytic Enantioselective Michael-Michael-
Aldol-Henry Reaction Cascade for the One Pot Synthesis of
Nor-Steroid Skeleton by Hong and Co-Workers[54]
In 2014, Hong and co-workers reported a one pot organocata-
lytic enantioselective double Michael/aldol/Henry cascade reac-
tions to assemble enantiomerically enriched nor-steroid 181
from simple precursors 172 and 173.[54] This approach is based
on the organocatalytic union of 172 and 173 catalyzed by the
organocatalyst 158 (Scheme 35). This transformation represents
the key step in the sequence leading to 181 and proceeds
through the initial formation of iminium ion 175 from 173 and
Minireview
prolinol derivative 158.[57] Iminium 175 undergoes a subse-
quent Michael reaction with nitronate anion 176 derived from
172. This transformation proceeds with high levels of stereo-
control at the newly formed carbon stereocenter; however, a
ca. 1:1 mixture of diastereomers at the stereocenter containing
the nitro- group is formed. The chiral prolinol portion of the
resultant adduct 177 is of great importance for controlling the
stereochemistry of the subsequent intramolecular Michael addi-
tion of enamine into enone to provide intermediate 178, which
subsequently undergoes hydrolysis to form aldehyde 174 as a
1:1 mixture of epimers at the nitro- group containing stereocen-
ter. This transformation was followed by in situ addition of pTsA
Scheme 35. One pot construction of nor-cardenolide core 181 by Hong and co-workers.[54]
Scheme 36. Synthesis of (+)-estrone by enantioselective Torgov's cyclization using chiral acid 201.[55]
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that led to intramolecular aldol condensation to form the mix-
ture of 179 and 180 epimeric at the NO2-containing stereocen-
ter. The one-pot sequence leading to 181 was then completed
by the sequential addition of DBU followed by TBAF. Both rea-
gents promoted the intramolecular Henry reaction by deproto-
nation leading to nitronate intermediate 182; however, the ad-
dition of DBU triggered the cyclization of 179 while TBAF was
required for the reaction of 180 to happen. The cyclization pre-
sumably proceeds through the transition state 182B (rather
than 182A) and leads to the natural configuration of the CD
ring junction. The desired product 181 was obtained in 47 %
yield over the entire single pot sequence as a single isomer.
Minireview
It is absolute and relative configurations corresponded to the
stereochemistry observed for the natural cardiotonic steroids.
4.3. Organocatalytic Chiral Brønsted Acid-Catalyzed
Synthesis of Estrogen by List and Co-Workers[55]
While many applications of organocatalysis in synthesis of
steroids are based on the exploration of chiral amine catalysis,
other applications started to immerge in recent years. Thus, in
2014, Benjamin List's group reported an asymmetric synthesis
of (+)-estrone that was enabled by the chiral Brønsted acid
catalysis (cf. Scheme 36).[55] This synthesis was based on the
racemic approach by Torgov, who in 1963, described an acid-
catalyzed cyclization of easily available diketone 184 into a
steroidal Δ8,14-dienone 186, which is a useful precursor to vari-
ous steroids including estrone.[58] Even though Torgov's cycliza-
tion-represents an efficient way to generate racemic steroidal
scaffolds, the development of the corresponding enantioselec-
tive variants has always been elusive.[59] Mechanistically, the de-
veloped Torgov's cyclization involves four sequential acid-cata-
lyzed steps: 1) isomerization of exocyclic Δ9,11-olefin in com-
pound 184 to the endocyclic Δ8,9-isomer 187; 2) intramolecular
Prins-type cyclization through 188 leading to a stabilized carbo-
cation 189; 3) deprotonation of carbocation 189 to give iso-
meric mixture of olefins 190, and 4) isomerization and dehydra-
tion of 190 to furnish Torgov's diene 186. List's group realized
that the likely stereo-determining step, the cyclization of 188
to 189, could potentially be catalyzed by using chiral Brønsted
acid.[60] In fact, upon screening of various chiral Brønsted acids,
a unique chiral disulfonamide (DSI) catalyst 185 containing
SF5- and NO2- substituents was found to catalyze the cyclization
in high yield and high enantioselectivity (95 % yields, 93 % ee).
A single recrystallization essentially provided enantiopure com-
pound 186 (>99.8 % ee). It is noteworthy that precious DSI cat-
alyst 185 could be recovered in 88 % yield and reused following
the acidification with similar efficacy. Diene 186 was then suc-
cessfully converted to (+)-estrone by using two-step diastereo-
selective reduction protocol developed by E. J. Corey.[61] This
sequence included stepwise reduction of first Δ14- (Pd/C, H2,
Et3SiH) and then Δ8- (CF3CO2H, TBAI, Et3SiH) alkene moieties
followed by the deprotection of (+)-estrone methyl ether with
BBr3.
5. Conclusion and Outlook
This minireview has highlighted some recent progress in the
synthesis of steroids that was enabled by the advances in catal-
ysis. The rapid progression of the field of catalysis has greatly
expanded the toolbox of a synthetic organic chemist and pro-
vided new powerful transformations that allow to install com-
plex functionalities in a highly selective and mild manner. This
has resulted in many new and creative approaches to complex
steroidal skeletons that feature high efficiency and allow to ac-
complish multiple steps in a single reaction pot. Such ap-
proaches provide robust platforms for the subsequent medici-
nal chemistry exploration of steroids and other related natural
products and their derivatives.
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